Skip to main content
. 2009 Apr 22;83(13):6779–6789. doi: 10.1128/JVI.02443-08

FIG. 3.

FIG. 3.

Tumor-specific HPV-16 L1-specific CD8+ CTL responses induced by L1-pulsed DCs in Kcx19, Kcx21, and Kcx22 patients, measured in a 5-h 51Cr-release assay. Percentage lysis against autologous tumor cells and HLA-identical HPV-16-negative control LCL at different effector/target cell ratio is shown. Anti-HLA class I blocking antibody (W6/32) was used at 50 μg/ml. A representative experiment for each patient is shown.